Physician profile
Mark J Dukaj
NPI 1285636639
$5,533.21
in general payments reported to CMS, 2019-2025
29 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $1,275 · 2022: $290 · 2023: $972 · 2024: $1,001 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,199.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,483.58 | 2019-2025 | |
| Abbvie INC. | $477.91 | 2022-2025 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals LP | $459.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $446.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $415.40 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $371.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $314.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Idorsia Pharmaceuticals US INC | $178.82 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $154.49 | 2024-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $149.55 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Xeris Pharmaceuticals, INC. | $131.78 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Amgen INC. | $119.46 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Abbott Laboratories | $118.89 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $89.31 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $82.50 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $73.85 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $65.84 | 2019 | |
| Astellas Pharma US INC | $54.15 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $53.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.83 | 2019-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $38.44 | 2023-2024 | Gemtesa |
| Medtronic, INC. | $31.36 | 2023 | Interstim |
| Phathom Pharmaceuticals, INC. | $28.16 | 2023 | Voquezna |
| Smith+Nephew, INC. | $26.94 | 2019 | |
| Merck Sharp & Dohme LLC | $23.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.28 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dukaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.